A new era of antiretroviral drug toxicity.
The spectrum of drugs used in HIV-infected patients has dramatically changed since triple antiretroviral combinations were introduced, albeit at the expense of some severe adverse events, in 1996. Abandonment of stavudine in countries that can afford it, new drugs from new classes with a wide therapeutic window and the impressive scale-up of drug access in resource-limited settings are several of the key new events. Drug safety is likely to be the most important factor to distinguish one antiretroviral regimen from another. We review life-threatening adverse events, adverse events of new investigational or recently marketed drugs, adverse events with a genetic component and tissue-specific adverse events of fat, heart, bone, kidney and liver.
Calmy
Alexandra
A
Geneva University Hospital, HIV Unit, Geneva, Switzerland. alexandra.calmy@hcuge.ch
Hirschel
Bernard
B
Cooper
David A
DA
Carr
Andrew
A
D044966:Anti-Retroviral Agents / Q000009:adverse effects*; D001851:Bone Diseases, Metabolic / Q000139:chemically induced; D002318:Cardiovascular Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D004341:Drug Evaluation; D014644:Genetic Variation; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced; D006295:Health Resources; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced
D044966:Anti-Retroviral Agents